Examining the role of epigenetic age in myeloproliferative neoplasms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the relationship between epigenetic age and clinical outcomes in patients with myeloproliferative neoplasms (MPN), including essential thrombocythemia, polycythemia vera, and primary myelofibrosis. By analyzing DNA methylation patterns at diagnosis, the study aims to determine how epigenetic age correlates with thrombotic events and the progression of these hematological malignancies. The research utilizes established epigenetic clocks to assess aging and its potential impact on patient prognosis. The findings could enhance understanding of MPN complications and improve risk stratification for affected individuals.

Why it matters

Who can join: the full rules

Inclusion Criteria:

For the 110 patients with MPN:

* Patients with PV, ET or PMF
* DNA extracted from purified granulocytes at time of diagnosis
* No treatment likely to impact DNA methylation (chemotherapy, immunosuppressants in particular)

For the 10 subjects without MPN:

* Absence of hematological malignancy
* Search for JAK2V617F mutation in the context of reactive thrombocytosis or secondary polycythemia
* Absence of treatment likely to impact DNA methylation (chemotherapy, immunosuppressants in particular)

Exclusion Criteria:

For the 110 patients with MPN:

* Patients without PV, ET or PMF
* Patients without purified granulocytes DNA available at time of diagnosis
* Patients treated by cytoreductive drug, demethylating agent, chemotherapy or immunosuppressive therapy at the time of DNA sampling
* Patients with less than 2 years' follow-up

For the 10 subjects in NMP :

* Patients with hematological malignancy and/or solid cancer
* Patients treated by cytoreductive drug, demethylating agent, chemotherapy or immunosuppressive therapy at the time of DNA sampling

Where it's running

• CHU de Bordeaux, service Hématologie Biologique
  Bordeaux, France Recruiting

Study contacts

• Study coordinator: Olivier MANSIER
• Email: olivier.mansier@chu-bordeaux.fr

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Caris Chromoseq data collection for AML, MDS, and MPN

  This study tests how well the Caris Chromoseq assay helps categorize risk in patients with AML, MDS, or MPN compared with standard tests.

  Recruiting Caris Science, Inc. · Phoenix, Arizona · NCT07680868

• Using NETosis blood markers to predict clot risk in JAK2-positive myeloproliferative neoplasms

  This study will try to see if blood markers of NETosis can predict clotting risk in people with JAK2V617F-positive myeloproliferative neoplasms who are at high risk for thrombosis.

  Recruiting University Hospital, Bordeaux · Angers and 14 other locations · NCT07119970

• CMV Triplex vaccine to boost immunity and prevent CMV after haploidentical stem cell transplant

  This trial tests whether giving a CMV-MVA Triplex vaccine to donors and/or recipients, with or without the antiviral letermovir, can boost CMV immunity and prevent CMV viremia in people having haploidentical stem cell transplants.

  Recruiting at 3 sites Phase 1 City of Hope Medical Center · Duarte, California and 2 other locations · NCT07020533

• Vedolizumab with post-transplant cyclophosphamide and short-course tacrolimus to prevent graft-versus-host disease after reduced-intensity allogeneic stem cell transplant

  This trial tests whether adding vedolizumab to post-transplant cyclophosphamide and a short course of tacrolimus can prevent graft-versus-host disease in adults getting reduced-intensity allogeneic stem cell transplants for leukemias or related blood disorders.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT06815003

• Study of characteristics and complications in young patients with myeloproliferative neoplasia

  This study is trying to gather information about young people under 30 with myeloproliferative neoplasia to better understand their health and complications.

  Recruiting University Hospital, Brest · Brest · NCT06715267

• Using Sorafenib to Prevent Relapse After Stem Cell Transplantation

  This study is testing if the drug sorafenib can help prevent relapse in patients with high-risk blood cancers after they receive a stem cell transplant.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT06532084

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.